Takamasa Hotta

Dr. Takamasa Hotta

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 March 2019 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TOTamio Okimoto
Tamio Okimoto
YTYukari Tsubata
Yukari Tsubata
THTakamasa Hotta
Takamasa Hotta
MHMegumi Hamaguchi
Megumi Hamaguchi
MNMika Nakao
Mika Nakao
TITakeshi Isobe
Takeshi Isobe
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

1 January 2013 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
PDF file
FKFumi Karino
Fumi Karino
KMKiyotaka Miura
Kiyotaka Miura
HFHiroshi Fuchita
Hiroshi Fuchita
NKNaoya Koba
Naoya Koba
ENEmiko Nishikawa
Emiko Nishikawa
TITakeshi Isobe
Takeshi Isobe

3 February 2021 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
THTakamasa Hotta
Takamasa Hotta
TOTakae Okuno
Takae Okuno
MNMika Nakao
Mika Nakao
YAYoshihiro Amano
Yoshihiro Amano
TITakeshi Isobe
Takeshi Isobe
YTYukari Tsubata
Yukari Tsubata
Due to the emergence of immune checkpoint inhibitors, the abscopal effect has gained more attention. We report a case of extracranial abscopal effect after whole‐brain irradiation therapy due to brain metastasis. After the initial abscopal effect was confirmed, a second abscopal effect was confirmed following radiation therapy for bone metastases. This case confirms the reproducibility of the abscopal effect. Moreover, the abscopal effect was not observed in metastatic lesions with low immunogenicity, even in the same patient.

20 November 2019 in Geriatrics & Gerontology International
Verified
Journal Article
Open access
PDF file
YTYukari Tsubata
Yukari Tsubata
YSYohei Shiratsuki
Yohei Shiratsuki
TOTakae Okuno
Takae Okuno
ATAkari Tanino
Akari Tanino
MNMika Nakao
Mika Nakao
TITakeshi Isobe
Takeshi Isobe
Aim: In Japan, the number of older patients with cancer has been increasing. Assessment of performance status, cognitive function and social background is necessary for the treatment of older patients. The aims of the present study were: (i) to establish an evaluation system using electronic medical records; and (ii) to distinguish older patients as fit versus vulnerable or frail according to a geriatric assessment (GA) system score.Methods: We incorporated GA tools in our electronic medical records system and carried out comprehensive assessments for patients with newly diagnosed lung cancer aged ≥65 years. The decision about primary treatment followed consultation with the clinical team and was not guided by GA scores. Subsequent treatment and outcomes were recorded.Results: A total of 100 patients had completed GA. The average age was 75 years (range 65–94 years). Regarding GA results, 63% were positive on the Comprehensive Geriatric Assessment 7, 39% on the Vulnerable Elderly Survey‐13 and 84% on the Geriatric 8. The percentage of vulnerable patients (positive on all three GA) was significantly higher in the non‐standard therapy group (n = 19) than in the standard therapy group (n = 81; 78.9% vs 21.0%, P < 0.001). Among vulnerable patients who received standard therapy, 47% discontinued chemotherapy as a result of toxicity. Even if a patient was considered vulnerable based on GA scores, chemotherapy is possibly safe for those with EGFR mutations.Conclusions: We confirmed the feasibility of this system. During decision‐making for older patients with cancer, a combination of GA helps prevent undertreatment or overtreatment. Geriatr Gerontol Int 2019; 19: 1108–1111.

1 March 2022 in Respiratory Investigation
Verified
Journal Article
Open access
MHMegumi Hamaguchi
Megumi Hamaguchi
YTYukari Tsubata
Yukari Tsubata
ATAkari Tanino
Akari Tanino
YMYuki Mitarai
Yuki Mitarai
KHKojiro Hata
Kojiro Hata
TITakeshi Isobe
Takeshi Isobe
Some randomized controlled trials have evaluated the effects of low-dose computed tomography (CT) screening on lung cancer mortality in heavy smokers. Based on the results of those trials, our CT screening program recommended screening for people aged ≥40 years with a history of smoking. This retrospective study aimed to verify the validity of our CT screening program and elucidate the current state of CT screening program. We retrospectively examined lung cancer detection in 25,189 participants who underwent chest CT screening by a mobile low-dose CT screening unit in the 10-year period from April 2009 to March 2019. Participants were recruited at Japan Agricultural Cooperatives (JA) Shimane Kouseiren. Participants requested CT screening for lung cancer. CT images were read by two pulmonologists. Lung cancer was identified in 82 of the 25,189 participants over 10 years, an overall lung cancer detection rate (percentage of lung cancers detected among all participants) of 0.33%. Lung cancer among never smokers accounted for 54.9% of the detected cases. The lung cancer detection rate was similar for smokers versus never smokers. The stage IA detection rate (percentage of stage IA lung cancers among all lung cancers detected) was 62%, while the stage Ⅳ detection rate was 10%. Chest CT detected lung cancer in never smokers as well as current or former smokers. Our CT screening program was not effective for never smokers; thus, further study of the effectiveness of CT screening in never smokers is needed.